244 related articles for article (PubMed ID: 29534936)
1. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
[TBL] [Abstract][Full Text] [Related]
2. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors.
Xin M; Hei YY; Zhang H; Shen Y; Zhang SQ
Bioorg Med Chem Lett; 2017 May; 27(9):1972-1977. PubMed ID: 28325601
[TBL] [Abstract][Full Text] [Related]
5. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
Gong YP; Tang LQ; Liu TS; Liu ZP
Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
[TBL] [Abstract][Full Text] [Related]
9. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
Zhu J; Ke K; Xu L; Jin J
J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
[TBL] [Abstract][Full Text] [Related]
11. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
[TBL] [Abstract][Full Text] [Related]
12. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR study of potent and selective PI3Kδ inhibitors.
Bui M; Hao X; Shin Y; Cardozo M; He X; Henne K; Suchomel J; McCarter J; McGee LR; San Miguel T; Medina JC; Mohn D; Tran T; Wannberg S; Wong J; Wong S; Zalameda L; Metz D; Cushing TD
Bioorg Med Chem Lett; 2015 Mar; 25(5):1104-9. PubMed ID: 25666823
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.
Norman P
Expert Opin Ther Pat; 2014 Nov; 24(11):1277-82. PubMed ID: 25326077
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
[TBL] [Abstract][Full Text] [Related]
18. Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation.
Yang C; Xu C; Li Z; Chen Y; Wu T; Hong H; Lu M; Jia Y; Yang Y; Liu X; Deng M; Chen Z; Li Q; Ling Y; Zhou Y
Eur J Med Chem; 2021 Nov; 223():113661. PubMed ID: 34237636
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
20. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.
Ko E; Seo HW; Jung ES; Ju S; Kim BH; Cho H; Kim YJ; Park YM; Kim JS; Jung G
Hepatology; 2018 Dec; 68(6):2285-2300. PubMed ID: 30300952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]